Side-by-side · Research reference

BPC-157vsOvagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED9/53 cited

BTheoreticalHUMAN-REVIEWED2/42 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

01Mechanism of Action

Parameter

BPC-157

Ovagen

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011 Sikiric 2018

Ovarian tissue chromatin complexes

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Feedback intact?

No known endogenous receptor; mechanism still under investigation

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Ovagen

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Lower / starter dose

200 mcg / day

Conservative starter for new users.

—

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Theoretical / Russian-tradition

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

Reconstitution

Bacteriostatic water, 1–2 mL

—

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

—

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

—

Route

—

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

04Side Effects & Safety

Parameter

BPC-157

Ovagen

Injection site reaction

Mild irritation (anecdotal)

Possible mild erythema (SQ route)

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Long-term safety

Unknown beyond Phase 2 trial duration

Unknown — no PubMed-indexed RCTs

Drug interactions

None established

—

Reported adverse events

—

None documented in indexed literature

Theoretical hormonal effects

—

Ovarian stimulation — monitor for estrogen-sensitive conditions

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

05Administration Protocol

Parameter

BPC-157

Ovagen

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

—

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Ovagen

— no documented stacks